HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

MK0626

structure in first source

Also Known As:

MK-0626

Networked: 11 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - MK0626: 11

Experts

1.	Habibi, Javad: 2 articles (08/2014 - 06/2014)
2.	Hayden, Melvin R: 2 articles (08/2014 - 06/2014)
3.	Sowers, James R: 2 articles (08/2014 - 06/2014)
4.	Asahara, Takayuki: 1 article (01/2019)
5.	Barrera, Janos A: 1 article (01/2019)
6.	Brownlee, Michael: 1 article (01/2019)
7.	Duscher, Dominik: 1 article (01/2019)
8.	Fischer, Lauren H: 1 article (01/2019)
9.	Giacco, Ferdinando: 1 article (01/2019)
10.	Gurtner, Geoffrey C: 1 article (01/2019)

Related Diseases

1.	Insulin Resistance 03/01/2014 - "A recent study from Gallagher et al. aimed to investigate the effect of a new depeptidyl-peptidase-4 inhibitor, MK-0626, on bone turnover in a mouse model developing insulin resistance and diabetes (MKR mice). " 06/01/2014 - "WD-induced increases in DPP4 activation in the plasma and kidney and proteinuria in WD mice were abrogated by MK0626, although blood pressure and systemic insulin sensitivity were not improved. "
2.	Fibrosis (Cirrhosis) 10/01/2015 - "MK0626 treatment attenuated tacrolimus-induced renal dysfunction, tubulointerstitial fibrosis, and arteriolopathy. " 08/01/2014 - "WD consumption induced myocardial oxidant stress and fibrosis with amelioration by MK0626. " 01/01/2016 - "DPP-4I, MK0626, but not native incretins has protective effects against AAA in Ang II-infused Apoe－/－ mice via suppression of inflammation, proteolysis, and fibrosis in the aortic wall." 03/01/2016 - "In contrast, diabetic mice treated with MK-0626 exhibited modest cardiac hypertrophy, impairment of cardiac function, and dysregulated expression of genes and proteins controlling inflammation and cardiac fibrosis. "
3.	Inflammation (Inflammations) 01/01/2019 - "Lineage profiling of isolated cells from ischemic tissues revealed that MK-0626 administration has an inhibitory effect on unproductive inflammation. " 01/01/2016 - "DPP-4I, MK0626, but not native incretins has protective effects against AAA in Ang II-infused Apoe－/－ mice via suppression of inflammation, proteolysis, and fibrosis in the aortic wall." 03/01/2016 - "In contrast, diabetic mice treated with MK-0626 exhibited modest cardiac hypertrophy, impairment of cardiac function, and dysregulated expression of genes and proteins controlling inflammation and cardiac fibrosis. "
4.	Proteinuria 06/01/2014 - "WD-induced increases in DPP4 activation in the plasma and kidney and proteinuria in WD mice were abrogated by MK0626, although blood pressure and systemic insulin sensitivity were not improved. "
5.	Wounds and Injuries (Trauma) 01/01/2019 - "MK0626 treatment increased the number of BM-MPCs present in bone marrow and in diabetic wounds. " 01/01/2019 - "MK0626 treatment significantly accelerated wound healing and increased wound vascularity, SDF-1 expression, and dermal thickness in diabetic wounds. "

Related Drugs and Biologics

1.	Incretins
2.	Dipeptidyl-Peptidase IV Inhibitors
3.	Type 3 Cyclic Nucleotide Phosphodiesterases
4.	Glucagon-Like Peptide 1 (GLP 1)
5.	Oxidants (Oxidizing Agents)
6.	Tacrolimus (Prograf)
7.	Proteins (Proteins, Gene)
8.	Fenofibrate (CiL)
9.	Cilostazol (Pletal)